These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 26100495

  • 1. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M.
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [Abstract] [Full Text] [Related]

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 3. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [Abstract] [Full Text] [Related]

  • 4. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM, Park JY, Kim DY, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH.
    Antivir Ther; 2010 Oct; 15(2):235-41. PubMed ID: 20386079
    [Abstract] [Full Text] [Related]

  • 5. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
    Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, Kim GH, Lee CH.
    Liver Int; 2008 Jul; 28(6):814-20. PubMed ID: 18312291
    [Abstract] [Full Text] [Related]

  • 6. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Chien RN, Liaw YF.
    Best Pract Res Clin Gastroenterol; 2008 Jul; 22(6):1081-92. PubMed ID: 19187868
    [Abstract] [Full Text] [Related]

  • 7. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP.
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Nguyen MH, Keeffe EB.
    J Viral Hepat; 2009 Mar; 16(3):149-55. PubMed ID: 19236641
    [Abstract] [Full Text] [Related]

  • 10. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A, Jochum C, Canbay A, Schlaak J, Gerlich WH, Gerken G.
    Eur J Med Res; 2008 Oct 27; 13(10):472-5. PubMed ID: 19008175
    [Abstract] [Full Text] [Related]

  • 11. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M, Mangia G, Lampertico P.
    Liver Int; 2014 Feb 27; 34 Suppl 1():120-6. PubMed ID: 24373088
    [Abstract] [Full Text] [Related]

  • 12. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
    Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P, ANRS CO12 CirVir group.
    Gastroenterology; 2019 Mar 27; 156(4):997-1009.e5. PubMed ID: 30768988
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O.
    Clin Gastroenterol Hepatol; 2013 Jan 27; 11(1):88-94. PubMed ID: 23063679
    [Abstract] [Full Text] [Related]

  • 14. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK, Fontana RJ.
    Aliment Pharmacol Ther; 2012 Mar 27; 35(6):674-89. PubMed ID: 22257108
    [Abstract] [Full Text] [Related]

  • 15. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico P.
    Antivir Ther; 2005 Mar 27; 10(6):709-13. PubMed ID: 16218169
    [Abstract] [Full Text] [Related]

  • 16. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Giakoustidis D, Giouleme O, Papanikolaou V, Akriviadis E, Vasiliadis T.
    Transpl Infect Dis; 2016 Oct 27; 18(5):667-673. PubMed ID: 27421122
    [Abstract] [Full Text] [Related]

  • 17. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF.
    J Hepatol; 2017 Feb 27; 66(2):275-281. PubMed ID: 27639844
    [Abstract] [Full Text] [Related]

  • 18. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS, Saraf N, Saigal S, Mohanka R, Rastogi A, Goja S, Menon PB, Soin AS.
    Transpl Infect Dis; 2015 Jun 27; 17(3):329-33. PubMed ID: 25682715
    [Abstract] [Full Text] [Related]

  • 19. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J, Tischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P, Rohde P, Manns MP, Trautwein C, Tillmann HL.
    Z Gastroenterol; 2004 Jan 27; 42(1):15-8. PubMed ID: 14997399
    [Abstract] [Full Text] [Related]

  • 20. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL, VIRGIL Surveillance Study Group.
    J Hepatol; 2010 Apr 27; 52(4):493-500. PubMed ID: 20185191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.